Navigation Links
EORTC BOS 2 trial opens for patients with resectable liver metastases from colorectal cancer
Date:6/4/2013

Colorectal cancer (CRC) is the second most frequent cause of cancer-related mortality in both Europe and the United States. Treatment for patients with resectable hepatic metastases from colorectal cancer consists of surgery combined with chemotherapy, but recurrence is observed in two thirds of these patients. In order to improve the outcome for these patients, EORTC trial 40091 BOS 2 will test the efficacy of adding bevacizumab or panitumumab to the standard treatment, peri-operative FOLFOX 4 chemotherapy.

Bevacizumab is a monoclonal antibody which targets the vascular endothelial growth factor (VEGF), and blocking VEGF could deprive the cancer of required nutrients. Panitumumab targets the epidermal growth factor receptor (EGFR). EGFR gene expression is upregulated in approximately 60 to 80% of CRC cases, and this has been linked to poor survival.

Dr. Bernard Nordlinger, CHU Ambroise Pare AP-HP, Boulogne-Billancourt and Coordinator of this study, says "The objective of this trial is to determine a new standard of care for these patients." The randomized phase 2 EORTC trial will investigate if treatment with perioperative modified FOLFOX6 plus either bevacizumab or panitumumab improves progression-free survival and pathological response in patients with up to eight resectable liver metastases resulting from wild type KRAS CRC as compared to treatment with perioperative modified FOLFOX 6 alone.

Dr. Stephane Benoist, Assistance Publique, Hpitaux de Paris, Hopital De Bicetre AP-HP, Le Kremlin Bicetre and co-Coordinator of this study, says "Following the EPOC study, perioperative FOLFOX chemotherapy became the new standard of care in many countries for patients with resectable colorectal liver metastases. Nevertheless, most patients developed recurrence despite perioperative FOLFOX chemotherapy. One of the ways to improve long term prognosis is to intensify the perioperative chemotherapy. The BOS 2 study addresses a major clinical ques
'/>"/>

Contact: John Bean
john.bean@eortc.be
European Organisation for Research and Treatment of Cancer
Source:Eurekalert

Page: 1 2

Related medicine news :

1. EORTC study shows radiotherapy and surgery provide regional control for breast cancer patients
2. Markers in Cancer, a joint meeting by ASCO, EORTC & NCI, 7-9 Nov 2013 (diagnostic tutorial on 5-7)
3. EORTC study identifies patients with anaplastic oligodendroglioma that benefit from adjuvant PCV
4. EORTC led intergroup trial investigates Imatinib failure-free survival in patients with GIST
5. Media alert: 24th EORTC - NCI - AACR Symposium Molecular Targets and Cancer Therapeutics
6. New Hepatitis C Clinical Trial Now Enrolling at Avail Clinical Research near Orlando, Florida; Accepting M/F Patients with Hep C Age 18-65
7. Low Back Pain Clinical Trial Now Enrolling at Achieve Clinical Research in Birmingham, Alabama; Accepting M/F Patients with Chronic Low Back Pain Age 18-80
8. DePuy ASR Hip Implant Lawyers at Wright & Schulte LLC Pleased with Judge’s Decision to Uphold $8.3 Million Award in California DePuy ASR Hip Lawsuit Trial
9. True-Dose Pets Launches New Trial-Sized Product Line
10. Vaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Pretrial Order in Federal Transvaginal Mesh Litigation
11. CureLauncher Introduces Personalized Clinical Trial Matching Service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... Pitt Researchers ... the University of Pittsburgh School of Medicine are leading a five-year, $5 million ... sub-Saharan Africa. , A cooperative agreement awarded by the U.S. Agency for ...
(Date:8/3/2015)... Irving, Texas (PRWEB) , ... August 03, 2015 ... ... awarded an agreement to Seattle-based Genelex to offer pharmacogenetic lab testing and ... care and reduce health care costs. , Annually, more than 8.6 million ...
(Date:8/3/2015)... ... 2015 , ... Catalent Pharma Solutions, the leading global provider ... products, today welcomed the announcement by OPKO Health that the US Food and ... treatment for chronic kidney disease (CKD) and vitamin D insufficiency, which uses Catalent’s ...
(Date:8/3/2015)... Angeles, CA (PRWEB) , ... August 03, 2015 , ... ... dental services to help patients in need. Most people know that general health emergencies, ... emergency. Unfortunately, a fewer amount of people know where to turn to during a ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... of its industry-defining contract lifecycle management solution, as well as announced the date ... increase the speed and ease of contract management tasks as well as enhancements ...
Breaking Medicine News(10 mins):Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Novatus Unveils Milestone Software Release 2
... With changes in the nation,s healthcare system looming and overall ... for debut at the Wynn Las Vegas this November has ... into alternative careers. The Medical Fusion conference ( ... that is tapping into the growing frustration of physicians practicing ...
... Patient-360(TM) tool optimizes impact of patient education programs. ... For marketers in the pharmaceutical industry, building relationships ... Data Development Worldwide,s Patient-360(TM) market research tool allows ... the patient pathway and then to prioritize and ...
... staph bacteria is being transmitted between animals and ... News) -- Transmission of methicillin-resistant staphylococcus aureus (MRSA) ... the most common being infections of the skin, ... a review of clinical evidence. , "Pet owners ...
... succeed where others have failed , MONDAY, June 22 (HealthDay ... in the United States could prove to be the toughest ... can reach that long-elusive goal, it would not only guarantee ... history, experts say. , "Assuming that President Obama ...
... with Patient and Chamber , , ANAHEIM, Calif., June ... in technology for hyperbaric healthcare, today announced the availability of ... verification of all NFPA (National Fire Protection Association) ... to be fully integrated into any hyperbaric chamber. The new ...
... Meeting -- , , News Facts , , ... new report, IDC Health Insights , an advisory services ... ranked Oracle as the number one vendor for enterprise life sciences software ... Software Top 10 identifies the 10 leading enterprise and specialty software vendors ...
Cached Medicine News:Health News:Physician Dissatisfaction Leads to New Medical Conference 2Health News:Physician Dissatisfaction Leads to New Medical Conference 3Health News:Data Development Worldwide Helps Pharmaceutical Marketers Optimize Relationship Marketing to Patients 2Health News:A Pet's Bite Can Pass on MRSA 2Health News:Health-Care Reform Could Be Obama's Toughest Challenge 2Health News:Health-Care Reform Could Be Obama's Toughest Challenge 3Health News:Health-Care Reform Could Be Obama's Toughest Challenge 4Health News:Sechrist Industries Introduces Ground-Check System to Verify NFPA Ground Requirements in Hyperbaric Chambers 2Health News:Market Research Firm Cites Oracle as Top Software Vendor for the Life Sciences Industry 2Health News:Market Research Firm Cites Oracle as Top Software Vendor for the Life Sciences Industry 3
(Date:7/31/2015)... 31, 2015  In today,s ever-changing marketplace, call centers ... mobile, increasingly connected, and increasingly impatient with slow service. ... interaction channels and tools is driving call centers to ... According to research by benchmarking firm, Best ... segment in a call center study realize the impact ...
(Date:7/31/2015)... 31, 2015 More than 1,500 substance abuse ... convene in Indianapolis Aug. 2-6 ... Mid-Year Training Institute . The week-long training, held at ... one of our nation,s biggest public health challenges – ... Institute is a one-of-a-kind intensive training opportunity, offering more ...
(Date:7/31/2015)... July 31, 2015 RnRMarketResearch.com ... market research report that provides an overview of ... data sourced from in-house databases, secondary and primary ... needles market products pipeline spread across 124 pages, ... 73 tables and 5 figures is now available ...
Breaking Medicine Technology:Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Community Leaders From Across The Country Head To Indianapolis For CADCA 2015 Mid-Year Training Institute Aug. 2-6 2Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5
... DUBLIN, Feb. 15, 2011 Warner Chilcott plc (Nasdaq: ... and full year 2010 financial results prior to the market opening ... issuing a press release, the Company will host a conference call ... AM (Eastern Time) to review the results. To participate in the ...
... Boston Scientific Corporation (NYSE: BSX ) ... treat peripheral chronic total occlusions (CTOs).  These acquisitions add ... devices for lower extremity peripheral artery disease.   ... 2010 from S.I. Therapies, Ltd., based in Israel.  The ...
Cached Medicine Technology:Boston Scientific Acquires Two Novel Technologies to Treat Peripheral Chronic Total Occlusions 2Boston Scientific Acquires Two Novel Technologies to Treat Peripheral Chronic Total Occlusions 3Boston Scientific Acquires Two Novel Technologies to Treat Peripheral Chronic Total Occlusions 4
Acuity Astigmatism: Letter Acuity, Astigmatic Clock, Number Acuity, and Tumbling E Tests....
... laboratory analysis that measures a substance produced by ... Annual PSA testing is a safe and effective ... as prostate cancer. One BIOSAFE Collection Kit, ... BIOSAFE's CLIA Certified Laboratory, and review of results ...
Stereo Smile II also includes a blank card and tests,at 60, 120, 240 and 480 sec of arc., ,Smile Test II Includes:, 1 demonstration card, 1 pair pediatric 3-D viewers, 1 pair infant 3-D v...
... from 800 to 40 seconds ... as 2 years of age ... left to right., ,Randot Preschool ... #1: 200 & 100 sec ...
Medicine Products: